NASDAQ: STOKStoke Therapeutics Inc Stock
$31.62-0.97 (-2.98%)
Updated Aug 28, 2026
STOK Price
$31.62
Fair Value Price
N/A
Market Cap
$2.04B
52 Week Low
$18.80
52 Week High
$40.22
P/E
-9.38x
P/B
5.9x
P/S
78.3x
PEG
N/A
Dividend Yield
N/A
Revenue
$27.59M
Earnings
-$207.90M
Gross Margin
100%
Operating Margin
-808.9%
Profit Margin
-753.6%
Debt to Equity
0.14
Operating Cash Flow
-$178M
Beta
1.38
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
STOK Overview
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine STOK's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
STOK
Ranked#337 of 463
Ranked#337 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.06 | A | |
| $113.88 | A | |
| $6.95 | A |
Be the first to know about important STOK news, forecast changes, insider trades & much more!
STOK News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how STOK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STOK is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
STOK is poor value based on its book value relative to its share price (5.9x), compared to the US Biotechnology industry average (5.46x)
P/B vs Industry Valuation
STOK is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more STOK due diligence checks available for Premium users.
Valuation
STOK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-9.38x
Industry
16.84x
Market
40.56x
STOK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.9x
Industry
5.46x
STOK is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STOK's financial health
Profit margin
Revenue
$9.3M
Net Income
-$61.6M
Profit Margin
-660.8%
STOK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
STOK's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$394.0M
Liabilities
$48.4M
Debt to equity
0.14
STOK's short-term assets ($322.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STOK's short-term assets ($322.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STOK's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
STOK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$56.6M
Investing
$9.0M
Financing
$1.9M
STOK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
STOK vs Biotech Stocks
Stoke Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.